AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24332196 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg ivabradine
Number of subjects: 36
Study 24332196 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg ivabradine
Number of subjects: 36
Study 21710403 — intervention group
Group type: EXPERIMENTAL
Intervention: No-dose-reduction group (initial optimal therapeutic doses continued throughout the study)
Number of subjects: 374
Study 21710403 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week group (initial optimal therapeutic doses continued for 4 weeks followed by a half dose reduction)
Number of subjects: 374
Study 21710403 — intervention group
Group type: EXPERIMENTAL
Intervention: 26-week group (initial optimal therapeutic doses continued for 26 weeks followed by a half dose reduction)
Number of subjects: 374
Study 21710403 — intervention group
Group type: EXPERIMENTAL
Intervention: Underweight at study entry
Number of subjects: 374
Study 21710403 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal weight at study entry
Number of subjects: 374
Study 21710403 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight at study entry
Number of subjects: 374
Study 21710403 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight change
Number of subjects: 374
Study 19112032 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol 100mg twice a day
Number of subjects: 106
Study 19112032 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 106
Study 16228997 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil 10 mg/day
Number of subjects: 17
Study 16228997 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 15178177 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task condition (considering both tasks equally important)
Number of subjects: 43
Study 15178177 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task condition (focusing preferentially on one task)
Number of subjects: 43
Study 15178177 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective mental effort rating
Number of subjects: 43
Study 15178177 — intervention group
Group type: COMPARATOR
Intervention: Subjective mental effort variation according to task condition
Number of subjects: 43
Study 11280845 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy regimen A
Number of subjects: 2
Study 11280845 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy regimen B
Number of subjects: 2
Study 9263085 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltanolone (0.41 +/- 0.1 mg/kg)
Number of subjects: 75
Study 9263085 — intervention group
Group type: COMPARATOR
Intervention: Thiopental (2.88 +/- 0.62 mg/kg)
Number of subjects: 75
Study 9263085 — intervention group
Group type: COMPARATOR
Intervention: Etomidate (0.26 +/- 0.06 mg/kg)
Number of subjects: 75
Study 8001359 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiography readings by cardiologists
Number of subjects: 902
Study 8001359 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiography readings by sonographers
Number of subjects: 902
Study 8001359 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiography readings by different sonographers
Number of subjects: 902
Study 8001359 — intervention group
Group type: EXPERIMENTAL
Intervention: Interreader variability assessment
Number of subjects: 902
Study 8001359 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraclass correlation for LVM across visits
Number of subjects: 902
Study 2963759 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate plus oral placebo (group A, n = 7)
Number of subjects: 16
Study 2963759 — intervention group
Group type: COMPARATOR
Intervention: Leuprolide acetate plus oral medroxyprogesterone acetate (group B, n = 9)
Number of subjects: 16
Study 30457974 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-book online formative assessment covering the topic of the practical course
Number of subjects: 232
Study 30457974 — intervention group
Group type: COMPARATOR
Intervention: Formative assessment that did not cover the topic of the practical course
Number of subjects: 232
Study 29045304 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 35
Study 29045304 — intervention group
Group type: COMPARATOR
Intervention: SGA (other than clozapine)
Number of subjects: 35
Study 26268804 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass Drug Administration (MDA) with dihydroartemisinin plus piperaquine (DHAp)
Number of subjects: 5640
Study 26268804 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal Mass Drug Administration (fMDA) with dihydroartemisinin plus piperaquine (DHAp)
Number of subjects: 5640
Study 26268804 — intervention group
Group type: COMPARATOR
Intervention: No mass treatment (standard of care)
Number of subjects: 5640
Study 23448596 — intervention group
Group type: EXPERIMENTAL
Intervention: Failure-related priming
Number of subjects: 138
Study 23448596 — intervention group
Group type: EXPERIMENTAL
Intervention: Success-related priming
Number of subjects: 138
Study 23448596 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 138
Study 20890933 — intervention group
Group type: EXPERIMENTAL
Intervention: 220 ng of 2MD
Number of subjects: 157
Study 20890933 — intervention group
Group type: EXPERIMENTAL
Intervention: 440 ng of 2MD
Number of subjects: 157
Study 20890933 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study 18646709 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural clonidine 2 microg/kg
Number of subjects: 60
Study 18646709 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural clonidine 4 microg/kg
Number of subjects: 60
Study 18646709 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (C0 group)
Number of subjects: 60
Study 16787512 — intervention group
Group type: EXPERIMENTAL
Intervention: Timcodar dimesylate 12.5 mg/day
Number of subjects: 62
Study 16787512 — intervention group
Group type: EXPERIMENTAL
Intervention: Timcodar dimesylate 50 mg/day
Number of subjects: 62
Study 16787512 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 14504873 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg 1 h before operation (group R)
Number of subjects: 60
Study 14504873 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen sodium 550 mg 1 h before surgery (group N)
Number of subjects: 60
Study 14504873 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group P)
Number of subjects: 60
Study 14504873 — intervention group
Group type: COMPARATOR
Intervention: Rofecoxib and Placebo
Number of subjects: 60
Study 14504873 — intervention group
Group type: COMPARATOR
Intervention: Naproxen sodium and Placebo
Number of subjects: 60
Study 14504873 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib and Naproxen sodium
Number of subjects: 60
Study 10865480 — intervention group
Group type: EXPERIMENTAL
Intervention: Otosporin ear drops
Number of subjects: 60
Study 10865480 — intervention group
Group type: EXPERIMENTAL
Intervention: Otomize ear spray
Number of subjects: 60
Study 9108642 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg b.i.d. sodium valproate (VPA)
Number of subjects: 16
Study 9108642 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 mg b.i.d. sodium valproate (VPA)
Number of subjects: 16
Study 9108642 — intervention group
Group type: COMPARATOR
Intervention: Both doses of sodium valproate (VPA)
Number of subjects: 16
Study 8474201 — intervention group
Group type: EXPERIMENTAL
Intervention: HA-1A (10 mg.kg-1)
Number of subjects: 27
Study 8474201 — intervention group
Group type: COMPARATOR
Intervention: Control (human IgM antibody 10 mg.kg-1 and human serum albumin)
Number of subjects: 27
Study 8474201 — intervention group
Group type: EXPERIMENTAL
Intervention: HA-1A and combined-controls
Number of subjects: 27
Study 8474201 — intervention group
Group type: COMPARATOR
Intervention: Control human IgM antibody
Number of subjects: 27
Study 8474201 — intervention group
Group type: EXPERIMENTAL
Intervention: HA-1A
Number of subjects: 27
Study 3518984 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen 1 mg twice daily
Number of subjects: 29
Study 3518984 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 29623512 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback group (clinician received a visual display of symptom scores)
Number of subjects: 300
Study 29623512 — intervention group
Group type: COMPARATOR
Intervention: Control group (scores were not provided to clinicians)
Number of subjects: 300
Study 29623512 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback group
Number of subjects: 300
Study 29623512 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 300
Study 27381589 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoballoon ablation
Number of subjects: 750
Study 27381589 — intervention group
Group type: COMPARATOR
Intervention: RFC ablation
Number of subjects: 750
Study 27381589 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 750
Study 24588407 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisystemic Therapy adapted for health care settings (MST‐HC)
Number of subjects: 170
Study 24588407 — intervention group
Group type: COMPARATOR
Intervention: In-home family support (control)
Number of subjects: 170
Study 23350899 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 53
Study 23350899 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 53
Study 23350899 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril
Number of subjects: 53
Study 21813900 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-acting beta agonists
Number of subjects: 120
Study 21813900 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting bronchodilators
Number of subjects: 120
Study 21813900 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation
Number of subjects: 120
Study 21813900 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic obstructive pulmonary disease education
Number of subjects: 120
Study 21813900 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Number of subjects: 120
Study 21813900 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage of chronic obstructive pulmonary disease
Number of subjects: 120
Study 18176319 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV and trauma coping intervention
Number of subjects: 247
Study 18176319 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic support group intervention
Number of subjects: 247
Study 16964692 — intervention group
Group type: EXPERIMENTAL
Intervention: Midwife-assisted smoking cessation intervention (four midwife visits during pregnancy and one after delivery)
Number of subjects: 205
Study 16964692 — intervention group
Group type: EXPERIMENTAL
Intervention: Midwife-assisted smoking cessation intervention
Number of subjects: 205
Study 16964692 — intervention group
Group type: COMPARATOR
Intervention: Standard written information about health risks from maternal smoking to the fetus (control group)
Number of subjects: 205
Study 14564337 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin patch (15 mg/24 hours)
Number of subjects: 40
Study 14564337 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 11109297 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 0
Study 11109297 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent (premenstrual only) treatment with SSRIs
Number of subjects: 0
Study 8866346 — intervention group
Group type: EXPERIMENTAL
Intervention: Tagetes patula preparations plus protective pad
Number of subjects: 60
Study 8866346 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 1471435 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive team care (CC)
Number of subjects: 262
Study 1471435 — intervention group
Group type: COMPARATOR
Intervention: Traditional care (TC)
Number of subjects: 262
Study 6318224 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (5, 10 and 20 mg twice daily)
Number of subjects: 22
Study 6318224 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (40, 80 and 120 mg twice daily)
Number of subjects: 22
Study 30420001 — intervention group
Group type: EXPERIMENTAL
Intervention: In-treatment expectancy during antidepressant treatment
Number of subjects: 0
Study 30420001 — intervention group
Group type: EXPERIMENTAL
Intervention: Gap between expected treatment outcomes and actual depressive severity
Number of subjects: 0
Study 29853235 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-osteoperforations (MOPs)
Number of subjects: 32
Study 26813890 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary α-Linolenic Acid (ALA) intake meeting the recommendation (0.7% of total energy)
Number of subjects: 7202
Study 26813890 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-chain n-3 polyunsaturated fatty acids intake meeting the recommendation (≥500 mg/day)
Number of subjects: 7202
Study 26813890 — intervention group
Group type: EXPERIMENTAL
Intervention: Both ALA and long-chain n-3 polyunsaturated fatty acids recommendations met
Number of subjects: 7202
Study 25388488 — intervention group
Group type: EXPERIMENTAL
Intervention: Child feeding training program for primary care health professionals
Number of subjects: 619
Study 22891212 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of triglycerides plus heparin
Number of subjects: 0
Study 22891212 — intervention group
Group type: COMPARATOR
Intervention: Intravenous administration of glycerol
Number of subjects: 0
Study 22891212 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid infusion
Number of subjects: 0
Study 20587704 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 242
Study 20587704 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 242
Study 20587704 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 242
Study 17000647 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist
Number of subjects: 0
Study 17000647 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous oral progestin
Number of subjects: 0
Study 17000647 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 0
Study 16277782 — intervention group
Group type: EXPERIMENTAL
Intervention: GOS/FOS formula (6 g/l)
Number of subjects: 57
Study 16277782 — intervention group
Group type: EXPERIMENTAL
Intervention: Bb-12 formula (6.0x10(10) viable cells/litre)
Number of subjects: 57
Study 16277782 — intervention group
Group type: COMPARATOR
Intervention: Standard formula (non-supplemented)
Number of subjects: 57
Study 16277782 — intervention group
Group type: COMPARATOR
Intervention: Breast-fed infants (reference group)
Number of subjects: 57
Study 11997534 — intervention group
Group type: EXPERIMENTAL
Intervention: Radio-frequency (RF) ablation
Number of subjects: 72
Study 11997534 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous microwave coagulation (PMC)
Number of subjects: 72
Study 10542352 — intervention group
Group type: EXPERIMENTAL
Intervention: Texture analysis applied to MR images of the spinal cord in MS patients
Number of subjects: 0
Study 10542352 — intervention group
Group type: EXPERIMENTAL
Intervention: Texture analysis applied to MR images of the spinal cord in relapsing-remitting MS patients
Number of subjects: 0
Study 10542352 — intervention group
Group type: EXPERIMENTAL
Intervention: Texture analysis technique
Number of subjects: 0
Study 10542352 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmentation and texture analysis technique
Number of subjects: 0
Study 10542352 — intervention group
Group type: EXPERIMENTAL
Intervention: Texture analysis
Number of subjects: 0
Study 7782965 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary-surgical regimen (Group A): total pharyngo‐laryngo‐esophagectomy after 20 Gy irradiation therapy. Chemotherapy was combined in some patients.
Number of subjects: 60
Study 7782965 — intervention group
Group type: COMPARATOR
Intervention: Primary-radiotherapeutic regimen (Group B): radiation therapy (60 Gy) with chemotherapy (UFT 300 to 600 mg/day; some patients received 1-2 courses of intravenous cisplatinum).
Number of subjects: 60
Study 2109951 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside (10 micrograms/kg BW/min)
Number of subjects: 10
Study 2109951 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (10 micrograms/kg BW/min)
Number of subjects: 10
Study 2109951 — intervention group
Group type: EXPERIMENTAL
Intervention: Urapidil (bolus injections of 25, 25 and 50 mg, followed by an infusion of 180 ml/h)
Number of subjects: 10
Study 2109951 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (0.35 micrograms/kg BW/min)
Number of subjects: 10
Study 2109951 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 6106469 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol (beta-blocking drug)
Number of subjects: 5
Study 6106469 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 28822566 — intervention group
Group type: EXPERIMENTAL
Intervention: TheraCal
Number of subjects: 27
Study 28822566 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodentine
Number of subjects: 27
Study 28822566 — intervention group
Group type: EXPERIMENTAL
Intervention: ProRoot MTA
Number of subjects: 27
Study 25421272 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured allergy intervention (structured allergy history and skin prick testing with tailored advice on allergy avoidance)
Number of subjects: 0
Study 25421272 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 24078046 — intervention group
Group type: EXPERIMENTAL
Intervention: Terutroban
Number of subjects: 748
Study 24078046 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 748
Study 21854588 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive computer-navigated 'femur first' THA
Number of subjects: 0
Study 21854588 — intervention group
Group type: COMPARATOR
Intervention: Conventional minimally invasive THA procedure
Number of subjects: 0
Study 19936457 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary injection of 100 x 10^6 mononuclear cells (Arterial Group)
Number of subjects: 30
Study 19936457 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous injection of 100 x 10^6 mononuclear cells (Venous Group)
Number of subjects: 30
Study 19936457 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study 18607802 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized linear mixed models applied to longitudinal data sequences from clinical studies.
Number of subjects: 0
Study 16253719 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin alfa treatment group (n=78), median final dose 2,000 IU/wk
Number of subjects: 172
Study 16253719 — intervention group
Group type: COMPARATOR
Intervention: Control/delayed treatment group (n=94), median final dose 3,000 IU/wk
Number of subjects: 172
Study 16253719 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin alfa treatment group
Number of subjects: 172
Study 16253719 — intervention group
Group type: COMPARATOR
Intervention: Control/delayed treatment group
Number of subjects: 172
Study 16253719 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with stable Hgb levels
Number of subjects: 172
Study 16253719 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with decreasing Hgb levels
Number of subjects: 172
Study 11874008 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 90
Study 11874008 — intervention group
Group type: COMPARATOR
Intervention: Triclofos
Number of subjects: 90
Study 11874008 — intervention group
Group type: COMPARATOR
Intervention: Promethazine
Number of subjects: 90
Study 10440619 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib 50 mg
Number of subjects: 151
Study 10440619 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 151
Study 10440619 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study 7821104 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole (20 mg/day) alone
Number of subjects: 22
Study 7821104 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg/day) plus plaunotol (240 mg/day)
Number of subjects: 22
Study 2403470 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 4
Study 2403470 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenelzine
Number of subjects: 4
Study 2403470 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol and Phenelzine (both)
Number of subjects: 4
Study 331994 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanethidine 3% - adrenaline 0.5% (G-A)
Number of subjects: 19
Study 331994 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 30530058 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical changes in patient symptoms and quality of life
Number of subjects: 446
Study 30530058 — intervention group
Group type: EXPERIMENTAL
Intervention: Small clinical changes in chronically ill adults
Number of subjects: 446
Study 29354909 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture for 'regaining consciousness, benefiting marrow and opening orifices' and rehabilitation
Number of subjects: 40
Study 29354909 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture along the affected meridians and rehabilitation (Control group)
Number of subjects: 40
Study 26148681 — intervention group
Group type: EXPERIMENTAL
Intervention: One coaching session
Number of subjects: 0
Study 26148681 — intervention group
Group type: EXPERIMENTAL
Intervention: Four coaching sessions
Number of subjects: 0
Study 26148681 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-evaluated communication competence by physicians
Number of subjects: 0
Study 26148681 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation of consultations by physicians and patients
Number of subjects: 0
Study 23271305 — intervention group
Group type: EXPERIMENTAL
Intervention: rs2516838 genotype
Number of subjects: 668
Study 23271305 — intervention group
Group type: EXPERIMENTAL
Intervention: rs2516839 genotype
Number of subjects: 668
Study 23271305 — intervention group
Group type: EXPERIMENTAL
Intervention: rs2516838 and rs2516839 polymorphisms
Number of subjects: 668
Study 21645007 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma transfusions
Number of subjects: 0